Viridian Therapeutics, Inc.\DE (VRDN) Total Current Liabilities (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Total Current Liabilities of $51.8 million for Q1 2026, up 53.6% year-over-year from $33.7 million in Q1 2025, and down 26.72% quarter-over-quarter from $70.7 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Total Current Liabilities (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Total Current Liabilities history runs 14 years deep, the most recent figure standing at $51.8 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 53.6% year-over-year to $51.8 million; the TTM figure through Mar 2026 stood at $51.8 million (up 53.6% YoY), while the FY2025 annual figure was $70.7 million, up 47.67% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $51.8 million, down from $70.7 million in the prior quarter.
- The five-year high for Total Current Liabilities was $70.7 million in Q4 2025, with the low at $14.4 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $33.3 million (2022), against an average of $36.1 million.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 144.57% in 2022, then fell 20.13% in 2023.
- Viridian Therapeutics, Inc.\DE's Total Current Liabilities stood at $33.3 million in 2022, then fell by 20.13% to $26.6 million in 2023, then jumped by 79.74% to $47.9 million in 2024, then soared by 47.67% to $70.7 million in 2025, then decreased by 26.72% to $51.8 million in 2026.
- Business Quant data shows VRDN's Total Current Liabilities at $51.8 million in Q1 2026, $70.7 million in Q4 2025, and $50.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | 63.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 63.79 Mn |
| Mar 31, 2026 | 51.81 Mn |
| Dec 31, 2025 | 70.70 Mn |
| Sep 30, 2025 | 50.70 Mn |
| Jun 30, 2025 | 52.59 Mn |
| Mar 31, 2025 | 33.73 Mn |
| Dec 31, 2024 | 47.87 Mn |
| Sep 30, 2024 | 41.36 Mn |
| Jun 30, 2024 | 36.76 Mn |
| Mar 31, 2024 | 26.13 Mn |
| Dec 31, 2023 | 26.64 Mn |
| Sep 30, 2023 | 23.25 Mn |
| Jun 30, 2023 | 28.66 Mn |
| Mar 31, 2023 | 29.59 Mn |
| Dec 31, 2022 | 33.35 Mn |
| Sep 30, 2022 | 25.21 Mn |
| Jun 30, 2022 | 21.39 Mn |
| Mar 31, 2022 | 14.39 Mn |
| Dec 31, 2021 | 13.64 Mn |
| Sep 30, 2021 | 14.34 Mn |